Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$91.87
+2.7%
$87.64
$76.02
$99.56
$17.34B0.311.35 million shs986,105 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$13.45
+4.0%
$15.59
$7.88
$16.88
$6.63B1.294.40 million shs3.73 million shs
Grifols, S.A. stock logo
GRFS
Grifols
$6.48
+2.9%
$7.09
$5.30
$12.15
N/A0.562.92 million shs1.40 million shs
Ono Pharmaceutical Co., Ltd. stock logo
OPHLF
Ono Pharmaceutical
$15.96
$16.50
$15.96
$20.63
N/A0.631,800 shs10 shs
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$12.96
+0.6%
$13.50
$7.09
$14.47
$14.53B1.0510.59 million shs7.03 million shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
+0.97%-2.21%+5.12%-3.82%-8.22%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-0.15%-6.78%-18.27%-12.19%+29.56%
Grifols, S.A. stock logo
GRFS
Grifols
+0.32%-3.67%+1.29%-14.29%-16.78%
Ono Pharmaceutical Co., Ltd. stock logo
OPHLF
Ono Pharmaceutical
0.00%0.00%-4.09%-9.75%-21.78%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
+0.16%-2.65%-7.27%+7.42%+54.25%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
4.6324 of 5 stars
3.33.00.03.31.82.53.1
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
3.2271 of 5 stars
2.34.00.00.31.93.31.3
Grifols, S.A. stock logo
GRFS
Grifols
3.3809 of 5 stars
2.85.00.00.01.30.03.8
Ono Pharmaceutical Co., Ltd. stock logo
OPHLF
Ono Pharmaceutical
N/AN/AN/AN/AN/AN/AN/AN/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
0.8123 of 5 stars
1.43.00.00.02.81.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.63
Moderate Buy$107.6117.13% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.57
Moderate Buy$16.7124.27% Upside
Grifols, S.A. stock logo
GRFS
Grifols
1.67
Reduce$10.5062.04% Upside
Ono Pharmaceutical Co., Ltd. stock logo
OPHLF
Ono Pharmaceutical
N/AN/AN/AN/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.70
Moderate Buy$13.786.31% Upside

Current Analyst Ratings

Latest BMRN, ELAN, OPHLF, GRFS, and TEVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/12/2024
Grifols, S.A. stock logo
GRFS
Grifols
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold ➝ Sell
3/8/2024
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Neutral$14.00
2/29/2024
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold$91.00
2/27/2024
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSell ➝ Sell$12.50 ➝ $14.00
2/27/2024
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$16.00 ➝ $17.00
2/27/2024
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$18.00 ➝ $19.00
2/23/2024
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$115.00 ➝ $107.00
2/23/2024
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$100.00
2/23/2024
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$100.00
2/12/2024
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$12.00 ➝ $19.00
2/5/2024
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$10.00 ➝ $11.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$2.42B7.17$1.85 per share49.54$26.29 per share3.49
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.42B1.50$2.39 per share5.63$12.63 per share1.06
Grifols, S.A. stock logo
GRFS
Grifols
$7.13BN/A$0.81 per share7.96$12.61 per shareN/A
Ono Pharmaceutical Co., Ltd. stock logo
OPHLF
Ono Pharmaceutical
$3.31BN/A$1.87 per share8.52$10.76 per shareN/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$15.85B0.92$3.54 per share3.66$7.25 per share1.79

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$167.65M$0.88104.4033.051.646.93%5.01%3.64%4/24/2024 (Confirmed)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$1.23B-$2.50N/A12.931.36-27.87%6.44%2.91%5/8/2024 (Confirmed)
Grifols, S.A. stock logo
GRFS
Grifols
$131.34MN/A0.004.760.251.84%1.73%0.66%N/A
Ono Pharmaceutical Co., Ltd. stock logo
OPHLF
Ono Pharmaceutical
$834.15M$1.858.6310.64N/A25.43%16.32%14.16%N/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
-$559M-$0.47N/A5.161.54-3.33%34.90%6.48%5/8/2024 (Confirmed)

Latest BMRN, ELAN, OPHLF, GRFS, and TEVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.26N/A-$0.26N/AN/AN/A  
5/8/2024N/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$0.49N/A-$0.49N/AN/AN/A  
4/24/2024N/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$0.6020$0.33-$0.2720N/AN/AN/A  
2/26/202412/31/2023
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.10$0.08-$0.02$0.45$1.00 billion$1.04 billion      
2/22/2024Q4 23
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$0.4450$0.49+$0.0450$0.41$639.53 million$646.21 million      
1/31/2024Q3 2024
Ono Pharmaceutical Co., Ltd. stock logo
OPHLF
Ono Pharmaceutical
$0.45$0.51+$0.06$0.51N/A$888.42 million
1/31/2024Q4 2023
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$0.73$0.98+$0.25$1.55$3.97 billion$4.46 billion

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Grifols, S.A. stock logo
GRFS
Grifols
N/AN/AN/AN/AN/A
Ono Pharmaceutical Co., Ltd. stock logo
OPHLF
Ono Pharmaceutical
N/AN/AN/AN/AN/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.12
2.51
1.57
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.92
2.75
1.35
Grifols, S.A. stock logo
GRFS
Grifols
1.24
2.83
1.32
Ono Pharmaceutical Co., Ltd. stock logo
OPHLF
Ono Pharmaceutical
N/A
3.52
3.04
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.23
1.02
0.69

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,401188.73 million185.26 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,300492.97 million489.82 millionOptionable
Grifols, S.A. stock logo
GRFS
Grifols
26,314N/AN/AOptionable
Ono Pharmaceutical Co., Ltd. stock logo
OPHLF
Ono Pharmaceutical
3,761N/AN/ANot Optionable
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
37,8511.12 billion1.11 billionOptionable

BMRN, ELAN, OPHLF, GRFS, and TEVA Headlines

SourceHeadline
Duality Advisers LP Takes Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)Duality Advisers LP Takes Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)
marketbeat.com - April 23 at 7:52 AM
Number of Cape pharmacies ditch Israeli medicines to become ‘Apartheid Free Zone’Number of Cape pharmacies ditch Israeli medicines to become ‘Apartheid Free Zone’
msn.com - April 19 at 7:21 AM
Alvotech, Teva signs deal to expand access for Humira biosimilar in U.S.Alvotech, Teva signs deal to expand access for Humira biosimilar in U.S.
msn.com - April 19 at 7:21 AM
Teva Pharmaceutical Industries Limited (NYSE:TEVA) to Post Q2 2025 Earnings of $0.57 Per Share, Zacks Research ForecastsTeva Pharmaceutical Industries Limited (NYSE:TEVA) to Post Q2 2025 Earnings of $0.57 Per Share, Zacks Research Forecasts
americanbankingnews.com - April 19 at 3:02 AM
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
zacks.com - April 18 at 12:16 PM
Teva, Alvotech Secure FDA Approval for Stelara Biosimilar with Early 2025 LaunchTeva, Alvotech Secure FDA Approval for Stelara Biosimilar with Early 2025 Launch
biospace.com - April 18 at 10:05 AM
Zacks Research Analysts Boost Earnings Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA)Zacks Research Analysts Boost Earnings Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
marketbeat.com - April 18 at 6:31 AM
USFDA approves Selarsdi injection for subcutaneous use to treat severe plaque psoriasis, active psoriatic arthritis: Alvotech, TevaUSFDA approves Selarsdi injection for subcutaneous use to treat severe plaque psoriasis, active psoriatic arthritis: Alvotech, Teva
medicaldialogues.in - April 17 at 5:34 PM
Migdal Insurance & Financial Holdings Ltd. Acquires 1,860,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)Migdal Insurance & Financial Holdings Ltd. Acquires 1,860,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)
marketbeat.com - April 17 at 2:37 PM
Alvotech and Teva win FDA approval of Stelara copyAlvotech and Teva win FDA approval of Stelara copy
thepharmaletter.com - April 17 at 12:31 PM
Alvotech and Teva gain FDA approval of SELARSDI for psoriasisAlvotech and Teva gain FDA approval of SELARSDI for psoriasis
pharmaceutical-technology.com - April 17 at 7:30 AM
Teva CEO Francis becomes highest paid TASE co execTeva CEO Francis becomes highest paid TASE co exec
en.globes.co.il - April 17 at 7:30 AM
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) TabletsTeva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
finance.yahoo.com - April 16 at 8:42 AM
Harel Insurance Investments & Financial Services Ltd. Has $297.89 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)Harel Insurance Investments & Financial Services Ltd. Has $297.89 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)
marketbeat.com - April 14 at 1:28 PM
Teva Pharmaceutical Industries (NYSE:TEVA) Trading Down 5.3%Teva Pharmaceutical Industries (NYSE:TEVA) Trading Down 5.3%
americanbankingnews.com - April 14 at 4:42 AM
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Average Recommendation of "Moderate Buy" from AnalystsTeva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Average Recommendation of "Moderate Buy" from Analysts
americanbankingnews.com - April 13 at 4:52 AM
Teva announces phase 3 study of Ajovy for prevention of migraine achieves primary and all secondary endpointsTeva announces phase 3 study of Ajovy for prevention of migraine achieves primary and all secondary endpoints
pharmabiz.com - April 13 at 1:45 AM
Teva Pharmaceutical Industries (NYSE:TEVA)  Shares Down 5.3% Teva Pharmaceutical Industries (NYSE:TEVA) Shares Down 5.3%
marketbeat.com - April 12 at 2:51 PM
Meitav Investment House Ltd. Acquires 1,950,500 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)Meitav Investment House Ltd. Acquires 1,950,500 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)
marketbeat.com - April 12 at 12:48 AM
Pfizer unit to settle Effexor XR antitrust claims in $39M dealPfizer unit to settle Effexor XR antitrust claims in $39M deal
msn.com - April 11 at 1:28 PM
Teva Confirms Efficacy, Safety Of AJOVY In Prevention Of Migraine - Quick FactsTeva Confirms Efficacy, Safety Of AJOVY In Prevention Of Migraine - Quick Facts
markets.businessinsider.com - April 11 at 1:28 PM
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in ChinaTeva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
businesswire.com - April 11 at 8:30 AM
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
businesswire.com - April 9 at 4:30 PM
Teva Pharmaceutical Industries Sees Unusually Large Options Volume (NYSE:TEVA)Teva Pharmaceutical Industries Sees Unusually Large Options Volume (NYSE:TEVA)
marketbeat.com - April 9 at 2:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BioMarin Pharmaceutical logo

BioMarin Pharmaceutical

NASDAQ:BMRN
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Elanco Animal Health logo

Elanco Animal Health

NYSE:ELAN
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Grifols logo

Grifols

NASDAQ:GRFS
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Ono Pharmaceutical logo

Ono Pharmaceutical

OTCMKTS:OPHLF
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.
Teva Pharmaceutical Industries logo

Teva Pharmaceutical Industries

NYSE:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.